ReviewCNS & neurological disorders drug targets2024
Artificial Intelligence in The Management of Neurodegenerative Disorders.
Review in CNS & neurological disorders drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Revolutionizing Neurodegenerative Disease Management: The Synergy of AI and Pharmacy.Current aging science · 2026Review
- The Bidirectional Relationship between Psoriatic Arthritis and Mental Health: A Comprehensive Review.Current rheumatology reviews · 2026Review
- Innovative Sensor-Based Approaches for Assessing Neurodegenerative Diseases: A Brief State-of-the-Art Review.Sensors (Basel, Switzerland) · 2025Review
- Artificial Intelligence-Driven Neuromodulation in Neurodegenerative Disease: Precision in Chaos, Learning in Loss.Biomedicines · 2025Review
- Role of Liposomes in the Treatment of Neurodegenerative Disorders: A Comprehensive Review.Central nervous system agents in medicinal chemistry · 2025Review
- Biobased Nanomaterials: Pioneering Innovations for Biomedical Advancements.Pharmaceutical nanotechnology · 2025Review
- Lipid-based Nanomedicine for Alzheimer's Disease: A Comprehensive Review of Recent Advances.Pharmaceutical nanotechnology · 2025Review
- Serotonergic Dynamics in Autism Spectrum Disorder: Unraveling the Intricate Connection.CNS & neurological disorders drug targets · 2025Review
- Unravelling the Microbiome's Role in Healing Diabetic Wounds.Current pharmaceutical biotechnology · 2025Review
- Vincristine in Cancer Therapy: Mechanisms, Efficacy, and Future Perspectives.Current medicinal chemistry · 2025Review
- The impact of artificial intelligence on drug discovery for neuropsychiatric disorders.EXCLI journal · 2025Review
- Harnessing Bioprinting Technologies for Diabetic Wound Regeneration.Current pharmaceutical biotechnology · 2025Review
- Mechanistic insights and therapeutic potential of astilbin and apigenin in diabetic cardiomyopathy.Heliyon · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative disorders are characterized by a gradual but irreversible loss of neurological function. The ability to detect and treat these conditions successfully is crucial for ensuring the best possible quality of life for people who suffer from them. The development of effective new methods for managing and treating neurodegenerative illnesses has been made possible by recent developments in computer technology. In this overview, we take a look at the prospects for applying computational approaches, such as drug design, AI, ML, and DL, to the treatment of neurodegenerative diseases. To review the current state of the field, this article discusses the potential of computational methods for early disease detection, quantifying disease progression, and understanding the underlying biological mechanisms of neurodegenerative diseases, as well as the challenges associated with these approaches and potential future directions. Moreover, it delves into the creation of computational models for the individualization of care for neurodegenerative diseases. The article concludes with suggestions for future studies and clinical applications, highlighting the advantages and disadvantages of using computational techniques in the treatment of neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.